Table 1 The IC₅₀ value of heteronemin-induced anti-proliferation in cancers

Brain cancer

7.12 μM (GBM)

9.58 μM (U87)

Cheng, M.H. et al.

[36]

Leukemia

approximate 2.8 μM (K562)

Schumacher, M. et al.

[42]

0.40 μg/mL (K562)

Chen, Y.C. et al.

[18]

0.16 μg/mL (HL60)

Chen, Y.C. et al.

[18]

0.11 μg/mL (Molt4)

Chen, Y.C. et al.

[18]

0.001 μM (K562)

Chang, Y.C. et al.

[7]

Melanoma

15.3 μM (SK-MEL)

Kamel, H.N. et al.

[9]

Oral cancer

0.37 μM (KB)

Wonganuchitmeta, S.N. et al.

[8]

Breast cancer

0.001 μM (T-47D)

Chang, Y.C. et al.

[7]

0.8672 μM (MDA-MB-231)

0.8779 μM (MCF-7)

Yang, Y.S.H., et al.

[10]

0.29 μM (MCF-7)

Wonganuchitmeta, S.N. et al.

[8]

11.2 μM (BT549)

Kamel, H.N. et al.

[9]

0.66 μM (MDA-MB-231)

0.65 μM (Hs578T)

0.70 μM (MCF-7)

0.77 μM (T47D)

Kittiwisut, S. et al.

[41]

Non-small cell lung cancer (NSCLC)

0.51 μM (A549)

0.48 μM (H1299)

Chung, C.C. et al.

[12]

5.12 μM (A549)

Cheng, M.H. et al.

[36]

14 μM (A549)

Alarif, W.M. et al.

[37]

Hepatocellular Carcinoma

12.55 μM (HepG2)

Cheng, M.H. et al.

[36]

20 μM (HepG2)

Alarif, W.M. et al.

[37]

10.4 μM (HA22T)

5.25 μM (HA59T)

Chang, W.T. et al.

[43]

Cholangiocarcinoma

4.4 μM (HuccT1)

3.9 μM (SSP-25)

Lin, H.Y. et al.

[44]

Renal carcinoma

1.57 μM (A498)

3.54 μM (ACHN)

Wu, S.Y. et al.

[38]

Colon cancer

0.001 μM (DLD-1 and HCT-116)

Chang, Y.C. et al.

[7]

0.39 μM (HT-29)

Wonganuchitmeta, S.N. et al.

[8]

Cervical carcinoma

0.45 μM (HeLa)

Wonganuchitmeta, S.N. et al.

[8]

0.82 μM (HeLa)

Kittiwisut, S. et al.

[41]

Ovarian cancer

3.4 μM (SKOV3)

Kamel, H.N. et al.

[9]

Prostate cancer

2.38 μg/mL (LNCap)

1.65 μg/mL (DU145)

6.11 μg/mL (PC-3)

Wu, J.C. et al.

[19]

1.4 μM (LNCap)

2.7 µM (PC-3)

Lee, M.G. et al.

[17]

35 µM (PC-3)

Alarif, W.M. et al.

[37]

0.66 µM (PC-3)

Kittiwisut, S. et al.

[41]